WO1998054318B1 - LOCUS DU GENE DBCCR1 SUPPRESSEUR DE TUMEUR SITUE DANS LA REGION 9q32-33 - Google Patents
LOCUS DU GENE DBCCR1 SUPPRESSEUR DE TUMEUR SITUE DANS LA REGION 9q32-33Info
- Publication number
- WO1998054318B1 WO1998054318B1 PCT/GB1998/001515 GB9801515W WO9854318B1 WO 1998054318 B1 WO1998054318 B1 WO 1998054318B1 GB 9801515 W GB9801515 W GB 9801515W WO 9854318 B1 WO9854318 B1 WO 9854318B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- dbccrl
- polypeptide
- cancer
- gene
- Prior art date
Links
- 230000001629 suppression Effects 0.000 title claims abstract 3
- 102100009626 BRINP1 Human genes 0.000 title abstract 4
- 101710040841 BRINP1 Proteins 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 claims abstract 13
- 206010005003 Bladder cancer Diseases 0.000 claims abstract 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract 5
- 150000007523 nucleic acids Chemical class 0.000 claims 43
- 108020004707 nucleic acids Proteins 0.000 claims 36
- 229920001184 polypeptide Polymers 0.000 claims 28
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 13
- 230000011987 methylation Effects 0.000 claims 11
- 238000007069 methylation reaction Methods 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 210000004027 cells Anatomy 0.000 claims 6
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 5
- 230000002779 inactivation Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 108091007521 restriction endonucleases Proteins 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 3
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000007819 coupling partner Substances 0.000 claims 2
- 230000001809 detectable Effects 0.000 claims 2
- 230000029087 digestion Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003612 virological Effects 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000000349 Chromosomes Anatomy 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000003296 Saliva Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 229940035893 Uracil Drugs 0.000 claims 1
- 210000002700 Urine Anatomy 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001976 enzyme digestion Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 230000001743 silencing Effects 0.000 abstract 1
- 230000001225 therapeutic Effects 0.000 abstract 1
Abstract
L'invention concerne l'identification d'un locus suppresseur de tumeur situé dans la région 9q32-33 et d'un gène se trouvant dans cette région. Ce gène est dénommé 'DBCCR1', équivalent de candidat n°1 correspondant à la région du chromosome qui est supprimée lors d'un cancer de la vessie. L'invention se rapporte en outre aux utilisations de cette découverte, en particulier dans le diagnostic, le traitement prophylactique et thérapeutique du cancer et en particulier du cancer de la vessie. Certaines formes de cancer en particulier sont liées au blocage du promoteur du DBCCR1 ou de ce gène, blocage provoqué par l'hyperméthylation.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU75425/98A AU752701B2 (en) | 1997-05-28 | 1998-05-26 | Tumour suppressor gene DBCCR1 at 9q32-33 |
| JP50036199A JP2002511749A (ja) | 1997-05-28 | 1998-05-26 | ９ｑ３２−３３での腫瘍サプレッサー遺伝子ＤＢＣＣＲ１ |
| EP98922966A EP0983355A1 (fr) | 1997-05-28 | 1998-05-26 | LOCUS DU GENE DBCCR1 SUPPRESSEUR DE TUMEUR SITUE DANS LA REGION 9q32-33 |
| CA002288235A CA2288235A1 (fr) | 1997-05-28 | 1998-05-26 | Locus du gene dbccr1 suppresseur de tumeur situe dans la region 9q32-33 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9710995.3 | 1997-05-28 | ||
| GBGB9710995.3A GB9710995D0 (en) | 1997-05-28 | 1997-05-28 | Tumour suppressor locus and gene at 9q32-33 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998054318A1 WO1998054318A1 (fr) | 1998-12-03 |
| WO1998054318B1 true WO1998054318B1 (fr) | 1999-02-11 |
Family
ID=10813172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1998/001515 WO1998054318A1 (fr) | 1997-05-28 | 1998-05-26 | LOCUS DU GENE DBCCR1 SUPPRESSEUR DE TUMEUR SITUE DANS LA REGION 9q32-33 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0983355A1 (fr) |
| JP (1) | JP2002511749A (fr) |
| AU (1) | AU752701B2 (fr) |
| CA (1) | CA2288235A1 (fr) |
| GB (1) | GB9710995D0 (fr) |
| WO (1) | WO1998054318A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743909B2 (en) * | 2002-06-17 | 2004-06-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTPN12 expression |
| US6617434B1 (en) | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
| US5871917A (en) | 1996-05-31 | 1999-02-16 | North Shore University Hospital Research Corp. | Identification of differentially methylated and mutated nucleic acids |
| AU8229598A (en) * | 1998-07-02 | 2000-01-24 | Imperial Cancer Research Technology Limited | Tumour suppressor gene dbccr1 at 9q32-33 |
| US6994991B1 (en) | 1998-11-18 | 2006-02-07 | North Shore - Long Island Jewish Research Institute | Identification of differentially methylated multiple drug resistance loci |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| JP2008029293A (ja) * | 2006-07-31 | 2008-02-14 | Hisamitsu Pharmaceut Co Inc | 癌の治療薬のスクリーニング方法及び癌の治療薬 |
| JP5697448B2 (ja) | 2007-09-17 | 2015-04-08 | エムディーエックスヘルス エスエー | 膀胱癌の検出のための新規なマーカー |
| US10113203B2 (en) | 2007-11-30 | 2018-10-30 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
| US9783857B2 (en) | 2007-11-30 | 2017-10-10 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
| US9670551B2 (en) | 2007-11-30 | 2017-06-06 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
| EP2217728A4 (fr) | 2007-11-30 | 2011-01-05 | Genomictree Inc | Coffret et puce de diagnostic pour le cancer de la vessie utilisant un gène marqueur de méthylation spécifique du cancer de la vessie |
| US9670552B2 (en) | 2007-11-30 | 2017-06-06 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
| US9797017B2 (en) | 2007-11-30 | 2017-10-24 | Genomictree, Inc. | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene |
| EP3512962A1 (fr) * | 2016-09-16 | 2019-07-24 | QIAGEN GmbH | Procédé de détermination d'une dégradation d'acide nucléique dans un échantillon dans lequel au moins deux amplicons chevauchants sont produits et deux sondes sont utilisées dans le procédé |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756668A (en) * | 1994-11-15 | 1998-05-26 | The Johns Hopkins University School Of Medicine | Hypermethylated in cancer polypeptide, HIC-1 |
-
1997
- 1997-05-28 GB GBGB9710995.3A patent/GB9710995D0/en active Pending
-
1998
- 1998-05-26 CA CA002288235A patent/CA2288235A1/fr not_active Abandoned
- 1998-05-26 AU AU75425/98A patent/AU752701B2/en not_active Ceased
- 1998-05-26 EP EP98922966A patent/EP0983355A1/fr not_active Withdrawn
- 1998-05-26 WO PCT/GB1998/001515 patent/WO1998054318A1/fr active IP Right Grant
- 1998-05-26 JP JP50036199A patent/JP2002511749A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells | |
| Liang et al. | Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival | |
| EP1527199B1 (fr) | Procedes de detection d'acide nucleique anormalement methyle dans des echantillons biologiques heterogenes | |
| Karpel et al. | Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins | |
| WO1998054318B1 (fr) | LOCUS DU GENE DBCCR1 SUPPRESSEUR DE TUMEUR SITUE DANS LA REGION 9q32-33 | |
| Oleinik et al. | Epigenetic silencing of ALDH1L1, a metabolic regulator of cellular proliferation, in cancers | |
| US20080221056A1 (en) | Early Detection and Prognosis of Colon Cancers | |
| WO2001076451A9 (fr) | Diagnostique de maladies associees au metabolisme | |
| CN101080499A (zh) | 针对表观遗传学上沉默的肿瘤抑制基因的基因组筛选 | |
| US20100092981A1 (en) | Methods of detecting hypermethylation | |
| US20060292564A1 (en) | Method and nucleic acids for the analysis of breast cell proliferative disorders | |
| Sekita et al. | Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines | |
| Peng et al. | Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma | |
| EP2492356B1 (fr) | Procédé de détection de l'ADN méthylé dans un échantillon | |
| Laner et al. | Hypomethylation of the XIST gene promoter in prostate cancer | |
| EP1964934A1 (fr) | Solution de traitement d'échantillons et kit de réactifs pour préparer des échantillons en vue d'une méthylation d'ADN | |
| Eriksson et al. | Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma | |
| Leśniak et al. | Epigenetic control of the S100A6 (calcyclin) gene expression | |
| WO2005017183A2 (fr) | Biomarqueurs geniques methyles servant a detecter le cancer | |
| Fajkusová et al. | Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173 | |
| KR102346174B1 (ko) | Eml4-alk 양성 비소세포폐암 환자의 치료 약물 선택을 위한 정보 제공 방법 및 alk 저해제 내성 비소세포폐암 치료용 조성물 | |
| US20040048278A1 (en) | Diagnosis of diseases associated with the human c-mos gene | |
| Mareš et al. | Methylation changes in promoter and enhancer regions of the WT1 gene in Wilms’ tumours | |
| KR101597806B1 (ko) | 난소암 환자의 항암제 치료 반응성 예측용 마커 | |
| KR101597805B1 (ko) | 유전자 프로모터의 CpG 메틸화 변화를 이용한 난소암의 항암제 치료 반응성 예측용 조성물 및 이의 이용 |